Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Introduction Preclinical studies suggest that angiotensin system inhibitors (ASI) and bevacizumab improve tumor perfusion and chemotherapy efficacy. We performed a retrospective study to examine whether concomitant ASI use during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) was associated with improved overall survival (OS) in patients with advanced nonsquamous, non–small‐cell lung cancer (NS‐NSCLC). Patients and Methods In a retrospective cohort study, adult patients diagnosed with stage IIIB or IV NS‐NSCLC between 2005 and 2011 were identified from tumor registries at 1 of 4 Kaiser Permanente regions. Survival differences between those who did and did not receive ASIs concomitant with chemotherapy (CP or CPB) were assessed using propensity score–matched proportional hazard models. OS was measured from the initiation of chemotherapy until death, disenrollment, or December 31, 2012. Results Of the 1465 CP and 348 CPB patients included, 273 (19%) and 78 (22%), respectively, received concomitant ASI. For CP patients with and without concomitant ASI exposure, median OS was 12.0 and 8.4 months, respectively (crude hazard ratio [HR], 0.72; 95% confidence interval [CI], 0.63‐0.84). For CPB patients, the comparable median OS was 14.9 and 11.9 months, respectively (crude HR, 0.77; 95% CI, 0.57‐1.02). Using propensity score–matched cohorts, the HR for concomitant ASI use was 0.73 (95% CI, 0.61‐0.88) for CP patients and 0.79 (95% CI, 0.51‐1.21) for CPB patients. Conclusion Concomitant ASI receipt during CP or CPB therapy for NS‐NSCLC was associated with improved survival, although the association was only statistically significant in the CP group. Micro‐Abstract Preclinical studies suggest that angiotensin system inhibitors (ASI) improve tumor perfusion and chemotherapy delivery. In a retrospective study of nearly 2000 patients with advanced non–small‐cell lung cancer, concomitant ASI receipt during carboplatin and paclitaxel (CP) without or with bevacizumab (CPB) for nonsquamous, non–small‐cell lung cancer was associated with improved survival, although the association was only statistically significant in the CP group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Austin, P. C. (2009) · Statistics in Medicine · doi:10.1002/sim.3697 · Cited by 6,758
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Self-citationNSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Cited by
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citationRenin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review
Laghlam, D., Jozwiak, M., & Nguyen, L. S. (2021) · Cells · doi:10.3390/cells10071767 · Cited by 96
Levin, V. A., Chan, J., Datta, M., Yee, J. L., & Jain, R. K. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2528-3 · Cited by 51
“Based on these observations and the suggestion that ASIs can improve survival of glioblastoma patients treated with bevacizumab [14] or NSCLC patients treated with carboplatin [13], we investigated whether glioma patients on cytotoxic chemotherapy and/or antiangiogenic agents have improved survival when under concomit…”
BackgroundSelf-citationCurrent Status of Research on Losartan in Tumour Therapy
Wang, H., Yuan, S., & Wang, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70985 · Cited by 11
Metadata
- Authors
- Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P.
- Venue
- Clinical Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2017-03
- Volume
- 18
- Issue
- 2
- Pages
- 189-197.e3
- ISSN
- 1525-7304 (ISSN-L)
- OpenAlex
- W2509882972
- Cited by
- 37
- References
- 6
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1016/j.cllc.2016.07.008
- The paper
- Menter, A. R., Carroll, N. M., Sakoda, L. C., Delate, T., Hornbrook, M. C., Jain, R. K., Kushi, L. H., Quinn, V. P., & Ritzwoller, D. P. (2017). Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2016.07.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.